Sanofi India Q3 Results 2024: Date and Time, Share Price and Target

News: Sanofi India, a prominent pharmaceutical and healthcare company, is set to announce its third-quarter (Q3) financial results for 2024. Investors and stakeholders eagerly await this update to gain insights into the company’s performance. In this article, we’ll cover the essential details related to Sanofi India’s Q3 results, including the date and time of the announcement, share price movements, and the target outlook.

Date and Time of Q3 Results Announcement

Sanofi India’s Q3 results for 2024 are scheduled to be revealed on October 25th, 2024. The management will present the findings during a live audio webcast with the financial community. The session will commence at 14:00 CET (8:00 am EST) and will include a Q&A segment.

Share Price and Market Expectations

Investors closely monitor Sanofi India’s share price movements around the time of quarterly results. While we cannot predict the exact share price, it’s essential to keep an eye on market sentiment and any significant developments within the company. Analysts and experts will analyze the financial data to assess the company’s health and growth prospects.

Target Outlook

The target outlook refers to the company’s projected performance and goals. Sanofi India’s management will likely provide insights into their expectations for the upcoming quarter and the full year. Investors should pay attention to any guidance regarding revenue, profitability, and strategic initiatives.

Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.

About Sanofi India Limited :

Sanofi India Limited is one of the entities through which Sanofi operates in India. Let’s delve into some key details about this pharmaceutical and healthcare company:

History and Evolution:

• Sanofi India was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited.

• Over the years, it underwent several name changes, including Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, and finally, Aventis Pharma Limited.

• Today, Sanofi India employs more than 3,000 employees across the country.

Shareholding Structure:

• Sanofi, a global leader in healthcare, and its 100% subsidiary – Hoechst GmbH, are the major shareholders of Sanofi India Limited.

• Together, they hold 60.4% of the company’s paid-up share capital.

Manufacturing Sites:

1. Sanofi India operates two manufacturing sites:

• One in Hyderabad

• Another in Goa

2. These sites adhere to stringent global quality guidelines and have approvals from regulatory agencies such as the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, Regierungspräsidium Darmstadt in Germany, and others.

3. Sanofi India manufactures various dosage forms, including tablets, capsules, eye/ear drops, ampoules, vials, creams, and ointments.

Product Range:

• Sanofi India offers a wide array of medicines across therapeutic areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System, and Anti-histamines.

• Its commitment to quality and safety extends to both domestic consumption and exports to countries like Russia, Ukraine, and other CIS countries.

As the date approaches, investors should mark their calendars for Sanofi India’s Q3 results announcement. Stay informed, watch the share price movements, and consider the management’s outlook to make informed investment decisions. Remember that investing involves risks, and it’s essential to consult with financial advisors before making any investment choices.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.